Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

AGM Statement

21 Oct 2011 07:00

RNS Number : 5846Q
ABCAM Plc
21 October 2011
 



For immediate release 21 October 2011

 

 

ABCAM PLC

("Abcam" or "the Company")

 

AGM Statement

Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, is this morning holding its Annual General Meeting. Michael Redmond, Abcam's Chairman, will make the following statement at the meeting: 

"Last month, at the time of the announcement of our preliminary results, we highlighted the uncertainty surrounding the levels of centrally funded research expenditure amongst Western economies. This uncertainty remains a feature of our markets and it is unlikely to change in the near future. However, in spite of this backdrop, our product portfolio and revenues continue to grow and we remain on track to meet the Board's profit expectations.

"Separately, we announced today the appointment of two new Non-Executive Directors, Murray Hennessy and Michael Ross, who will join the Board on 1 November 2011. Both Murray and Michael have outstanding e-commerce experience and I am delighted to welcome them to the Abcam Board. I look forward to their valuable input to the next stage of Abcam's growth."

 

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

 

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine

 

 

Notes for editors

 

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA. (USA), Eugene, OR. (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.

Abcam now has an online catalogue of over 79,000 products sourced from more than 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMDKKDKKBDBNKB
Date   Source Headline
2nd Mar 201812:43 pmRNSTotal Voting Rights
19th Feb 20188:44 amRNSBlock listing Interim Review
2nd Feb 20185:57 pmRNSHolding(s) in Company
1st Feb 201812:26 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSAbcam Signs Exclusive License Agreement with Roche
18th Jan 201812:02 pmRNSHolding(s) in Company
8th Jan 201812:00 pmRNSAbcam present at J.P. Morgan Healthcare Conference
5th Jan 20187:00 amRNSHalf Year Trading Update
3rd Jan 20189:10 amRNSTotal Voting Rights
12th Dec 201710:37 amRNSDirector/PDMR Shareholding
1st Dec 20173:07 pmRNSTotal Voting Rights
15th Nov 20177:00 amRNSResult of AGM and Directorate Change
14th Nov 20177:00 amRNSAGM Statement
6th Nov 20174:48 pmRNSDirector/PDMR Shareholding
6th Nov 20174:42 pmRNSDirector/PDMR Shareholding
6th Nov 20174:40 pmRNSDirector/PDMR Shareholding
1st Nov 20174:46 pmRNSTotal Voting Rights
30th Oct 20179:55 amRNSDirector/PDMR Shareholding
17th Oct 20173:06 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirectorate Change
3rd Oct 201711:16 amRNSTotal Voting Rights
22nd Sep 20173:32 pmRNSAnnual Financial Report
22nd Sep 20177:00 amRNSDirector/PDMR Shareholding
18th Sep 20174:36 pmRNSDirector/PDMR Shareholding
11th Sep 20177:00 amRNSPreliminary Results
1st Sep 20179:41 amRNSTotal Voting Rights
25th Aug 201711:00 amRNSHolding(s) in Company
17th Aug 201710:00 amRNSHolding(s) in Company
9th Aug 20173:18 pmRNSBlock listing Interim Review
1st Aug 20179:45 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSPre-Close Period Update
3rd Jul 20179:54 amRNSTotal Voting Rights
7th Jun 20174:23 pmRNSDirector/PDMR Shareholding
1st Jun 20172:41 pmRNSTotal Voting Rights
18th May 20173:17 pmRNSApplication for admission to trading
18th May 20177:00 amRNSFinal Performance-Based AxioMx Milestone Payment
3rd May 201711:25 amRNSDirector/PDMR Shareholding
2nd May 201710:27 amRNSTotal Voting Rights
18th Apr 20172:24 pmRNSDirector/PDMR Shareholding
10th Apr 20173:37 pmRNSDirector/PDMR Shareholding
3rd Apr 20171:53 pmRNSTotal Voting Rights
23rd Mar 20177:00 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSDirector/PDMR Shareholding
6th Mar 20177:00 amRNSInterim Results
1st Mar 20174:05 pmRNSTotal Voting Rights
9th Feb 20178:52 amRNSBlock listing Interim Review
1st Feb 201712:09 pmRNSTotal Voting Rights
10th Jan 20177:00 amRNSHalf Year Trading Update
3rd Jan 20174:34 pmRNSTotal Voting Rights
15th Dec 201611:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.